Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, has signed an agreement to license investigative antisense therapy AKCEA-ANGPTL3-LRx to pharmaceutical company Pfizer.
Johnson & Johnson has unveiled plans to invest over $500m in the next four years to help end the epidemics of HIV and tuberculosis (TB).
Icosavax announced the launch of the company with a $51 million Series A financing, led by Qiming Venture Partners USA and joined by Adams Street Partners, Sanofi Ventures and NanoDimension, with continuing support from its seed investors.
Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody.
Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing.
Lantheus Holdings has signed an agreement to acquire oncology company Progenics Pharmaceuticals in an all-stock transaction.
Swedish Orphan Biovitrum (Sobi) has agreed to acquire Dova Pharmaceuticals in a deal valued at around $915m.
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing.
Pfizer has expanded its collaboration with oncology software provider Flatiron Health to integrate and increase the application of real-world data further in its development of targeted cancer drugs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.